Case Study: Dicot Pharma accelerates Phase 2a trial execution with Viedoc

Dicot Pharma accelerates Phase 2a trial with Viedoc and achieves >90% diary compliance

Dicot Pharma, a Swedish biopharmaceutical company, needed to quickly advance its novel erectile dysfunction therapy from a first-in-human study to a multi-country Phase 2a trial. Their challenge was to efficiently capture patient data from five international sites while maintaining tight timelines. They partnered with their CRO, Clinical Trial Consultants, and the vendor Viedoc to implement a solution using Viedoc Clinic (EDC) and Viedoc Me (ePRO).

Using Viedoc's EDC and ePRO tools, the team streamlined workflows, introduced dynamic randomization, and captured patient-reported outcomes. The solution resulted in a high-quality trial with diary compliance exceeding 90%. Viedoc's platform enabled a fast setup and seamless execution, keeping the study on its aggressive schedule and accelerating the therapy's path to market.

Dicot Pharma